TCBPW Financial Statements From 2010 to 2025

TCBPW Stock  USD 0.02  0  6.75%   
TC BioPharm financial statements provide useful quarterly and yearly information to potential TC BioPharm plc investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on TC BioPharm financial statements helps investors assess TC BioPharm's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting TC BioPharm's valuation are summarized below:
Quarterly Earnings Growth
(0.87)
Revenue
2.9 M
Earnings Share
(0.75)
Revenue Per Share
29.639
There are over one hundred nineteen available fundamental measures for TC BioPharm, which can be analyzed over time and compared to other ratios. All traders should should double-check TC BioPharm's latest fundamental trends against the trends from 2010 to 2025 to make sure the company is sustainable. Market Cap is likely to drop to about 673 K in 2025. Enterprise Value is likely to climb to about (49.7 K) in 2025

TC BioPharm Total Revenue

0.0

Check TC BioPharm financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among TC BioPharm's main balance sheet or income statement drivers, such as Interest Income of 1.9 K, Depreciation And Amortization of 638 K or Interest Expense of 90.7 K, as well as many indicators such as Price To Sales Ratio of 0.5, Dividend Yield of 0.0 or PTB Ratio of 0.22. TCBPW financial statements analysis is a perfect complement when working with TC BioPharm Valuation or Volatility modules.
  
Check out the analysis of TC BioPharm Correlation against competitors.

TC BioPharm Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets10 M10.3 M9.8 M
Pretty Stable
Short and Long Term Debt Total1.5 M1.6 M3.8 M
Very volatile
Other Current Liabilities5.1 M2.8 M2.4 M
Slightly volatile
Total Current Liabilities9.4 M5.5 M5.8 M
Slightly volatile
Property Plant And Equipment Net3.2 M2.4 M4.7 M
Slightly volatile
Accounts Payable1.2 M2.1 M899.1 K
Slightly volatile
Cash2.3 M2.8 M1.5 M
Slightly volatile
Non Current Assets Total3.6 M2.9 M5.1 M
Slightly volatile
Cash And Short Term Investments2.3 M2.8 M1.5 M
Slightly volatile
Net Receivables1.4 M1.1 M2.4 M
Slightly volatile
Common Stock Shares Outstanding37.3 K35.5 K18.1 K
Pretty Stable
Liabilities And Stockholders Equity10 M10.3 M9.8 M
Pretty Stable
Non Current Liabilities Total1.3 M1.3 M6.5 M
Slightly volatile
Capital Lease Obligations2.1 M1.6 MM
Slightly volatile
Other Current Assets4.9 M4.7 M2.9 M
Very volatile
Total Liabilities10.4 M5.6 M12.2 M
Pretty Stable
Property Plant And Equipment Gross5.4 M6.1 M6.8 M
Slightly volatile
Total Current Assets5.2 M6.6 M4.6 M
Slightly volatile
Capital Stock1.8 K1.9 K1.3 M
Slightly volatile
Short Term Debt333.6 K351.1 K883.3 K
Pretty Stable
Intangible Assets523.9 K707.4 K397.7 K
Slightly volatile
Common Stock1.8 K1.9 K1.2 M
Slightly volatile
Short and Long Term Debt558.7 K588.1 K5.3 M
Slightly volatile

TC BioPharm Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Interest Income1.9 KK14.3 K
Slightly volatile
Depreciation And Amortization638 K567 K833.3 K
Slightly volatile
Interest Expense90.7 K95.5 K844.2 K
Slightly volatile
Selling General Administrative5.1 M7.4 M3.9 M
Slightly volatile
Gross Profit3.1 M4.4 M3.3 M
Very volatile
Other Operating Expenses6.2 M6.2 M8.9 M
Slightly volatile
Research Development5.9 MMM
Slightly volatile
Total Operating Expenses6.2 M6.2 M8.9 M
Slightly volatile
Reconciled Depreciation736.6 K569.7 K878.2 K
Slightly volatile
Selling And Marketing Expenses321.9 K362.1 K394.8 K
Slightly volatile

TC BioPharm Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Begin Period Cash Flow2.4 M4.3 M5.1 M
Slightly volatile
Depreciation732.8 K569.7 K876.4 K
Slightly volatile
Capital Expenditures94.4 K99.3 K1.4 M
Slightly volatile
Issuance Of Capital Stock3.3 M4.8 M3.2 M
Pretty Stable
Total Cash From Financing Activities8.9 M9.8 M5.5 M
Slightly volatile
End Period Cash Flow2.3 M2.8 M1.5 M
Slightly volatile
Change To Inventory2.3 M2.5 M2.8 M
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio0.50.526.0496
Slightly volatile
Days Sales Outstanding9.1810.3311.2615
Slightly volatile
Average Payables836.1 K1.2 M786 K
Slightly volatile
Stock Based Compensation To Revenue0.250.260.2645
Slightly volatile
Capex To Depreciation0.190.21.4546
Slightly volatile
Sales General And Administrative To Revenue1.141.951.1819
Slightly volatile
Research And Ddevelopement To Revenue3.012.272.5534
Very volatile
Capex To Revenue0.06840.0720.3879
Slightly volatile
Cash Per Share68.1671.75492
Pretty Stable
Income Quality2.51.611.8542
Slightly volatile
Intangibles To Total Assets0.04260.0620.0402
Slightly volatile
Current Ratio0.611.080.9553
Slightly volatile
Receivables Turnover25.4428.6231.207
Slightly volatile
Graham Number6687039.3 K
Pretty Stable
Capex Per Share3.94.11676
Slightly volatile
Revenue Per Share1.4 K1.3 K1.6 K
Slightly volatile
Interest Debt Per Share63.767.05K
Very volatile
Debt To Assets0.220.230.3865
Pretty Stable
Operating Cycle9.1810.3311.2615
Slightly volatile
Ebt Per Ebit1.060.560.9852
Pretty Stable
Long Term Debt To Capitalization0.290.320.3512
Slightly volatile
Quick Ratio0.611.080.9553
Slightly volatile
Net Income Per E B T0.860.970.8524
Pretty Stable
Cash Ratio0.250.470.28
Slightly volatile
Cash Conversion Cycle9.1810.3311.2615
Slightly volatile
Days Of Sales Outstanding9.1810.3311.2615
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.181.161.212
Slightly volatile
Fixed Asset Turnover0.551.050.6878
Slightly volatile
Debt Ratio0.220.230.3865
Pretty Stable
Price Sales Ratio0.50.526.0496
Slightly volatile
Asset Turnover0.330.390.3312
Very volatile

TC BioPharm Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap673 K708.4 K18.4 M
Slightly volatile

TCBPW Fundamental Market Drivers

Cash And Short Term Investments2.5 M

About TC BioPharm Financial Statements

TC BioPharm investors use historical fundamental indicators, such as TC BioPharm's revenue or net income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in TC BioPharm. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue-274.8 K-261.1 K
Stock Based Compensation To Revenue 0.26  0.25 
Sales General And Administrative To Revenue 1.95  1.14 
Research And Ddevelopement To Revenue 2.27  3.01 
Capex To Revenue 0.07  0.07 
Revenue Per Share1.3 K1.4 K
Ebit Per Revenue(3.61)(3.80)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for TCBPW Stock Analysis

When running TC BioPharm's price analysis, check to measure TC BioPharm's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy TC BioPharm is operating at the current time. Most of TC BioPharm's value examination focuses on studying past and present price action to predict the probability of TC BioPharm's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move TC BioPharm's price. Additionally, you may evaluate how the addition of TC BioPharm to your portfolios can decrease your overall portfolio volatility.